Derm Pract ConceptObservational study
Interplay of Biological Treatment and Psychological Features in Patients with Psoriasis
A Real-Life Prospective Study.
Moretta G, Samela T, Provini A, Pagnanelli G, Graceffa D, Orsini D, Lora V, Richetta AG, Dattola A, Amato S, Bernardini N, Tribuzi P, Zangrilli A, Vultaggio M, Bianchi L, Caldarola G, De Luca E, De Simone C, Giordano D, Masini C, Bavetta M, Lechiancole S, Panasiti V, Abeni D
Dermatology Practical & ConceptualIn the feed 10 Oct 2026, published online 31 Jul 2026, issue 2026 Jul 31, added to PubMed 10 Oct 2026
Topics: Psoriasis
Abstract
INTRODUCTIONEmotional dysregulation (ED), common among patients with psoriasis, leads to psychopathology and impairs treatment adherence.
OBJECTIVEThis study examined the changes in prevalence of ED in patients and its effects on illness perception, mental health, and quality of life (QoL) during one year of treatment with risankizumab.
METHODED, illness perception, general health, and QoL were measured at baseline, and at four, 16, and 52 weeks posttreatment in 58 patients with psoriasis.
RESULTSHigher ED was associated with greater psychological distress and poorer QoL. Patients with higher levels of ED reported greater psychological distress, worse QoL, and higher symptom-related distress throughout treatment as compared to those with lower ones. Although both groups improved in terms of illness perception and clinical severity outcomes, patients with high ED consistently experienced worse subjective outcomes.
CONCLUSIONED is frequent in psoriasis patients and negatively affects mental health and QoL, despite clinical improvements in skin symptoms. Targeted psychological interventions may be necessary for patients who exhibit higher levels of emotional dysregulation to ensure comprehensive care and better long-term outcomes.
Abstract from PubMed
PMID 42858446 · DOI 10.5826/dpc.1603a6163